Nowadays, CR3 antagonists are widely accepted as potential therapeutics to treat AD owing to their potential to significantly decrease the Aβ-induced proinflammatory molecules and ROS in microglia [92]. The gene discussed is CRIPTO3; the disease is Alzheimer disease.